Neurocrine Biosciences, Inc. (NBIX) Financials

NBIX Assets vs Liabilities

DateAssetsLiabilities
2024-03-31 3.5 billion 1.1 billion
2023-12-31 3.3 billion 1.0 billion
2023-09-30 2.8 billion 846.1 million
2023-06-30 2.6 billion 760.1 million

NBIX Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2024-03-31 119.1 million 44.5 million
2023-12-31 118.1 million 38.1 million
2023-09-30 204.4 million 47.8 million
2023-06-30 172.8 million 68.5 million

NBIX Net Income

No data available :(

NBIX Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2024-03-31 1.2 billion - 252.9 million
2023-12-31 1.0 billion - 258.3 million
2023-09-30 1.1 billion - 85.9 million
2023-06-30 976.7 million - 89.1 million

NBIX Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2024-03-31 103.6 million
2023-12-31 102.3 million
2023-09-30 101.1 million
2023-06-30 100.2 million

NBIX Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2024-03-31 11.2 million 154.1 million 243.1 million -
2023-12-31 5.4 million 137.5 million 218.9 million -
2023-09-30 7.6 million 142.2 million 204.2 million -
2023-06-30 6.8 million 145.8 million 221.8 million -

NBIX Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2024-03-31 515.3 million 12.8 million
2023-12-31 515.2 million 8.5 million
2023-09-30 498.8 million 11.2 million
2023-06-30 452.7 million 11.5 million

NBIX

Price: $143.19

52 week price:
89.04
148.37

Earnings Per Share: 2.47 USD

P/E Ratio: 53.35

Exchange: NMS

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Volume: 490000

Ebitda: 15.0 million

Market Capitalization: 14.4 billion

Links: